Nanoparticles have been widely explored for combined therapeutic and diagnostic applications. For example, lipid-based nanoparticles have been used to encapsulate multiple types of agents and achieve multi-functions. Herein, we enabled a co-delivery of mRNA molecules and superparamagnetic iron oxide nanoparticles (SPIONs) by using an amino-ester lipid-like nanomaterial. An orthogonal experimental design was used to identify the optimal formulation. The optimal formulation, MPA-Ab-8 LLNs, not only showed high encapsulation of both mRNA and SPIONs, but also increased the r 2 relaxivity of SPIONs by more than 1.5-fold in vitro. MPA-Ab-8 LLNs effectively delivered mRNA and SPIONs into cells, and consequently induced high protein expression as well as strong MRI contrast. Consistent herewith, we observed both mRNA-mediated protein expression and an evident negative contrast enhancement of MRI signal in mice. In conclusion, amino-ester nanomaterials demonstrate great potential as delivery vehicles for theranostic applications.
Introduction
In recent years, many efforts have been made to explore efficient chemical compositions and formulation methods for establishing effective platforms for mRNA delivery [1, 2] . Many of these delivery systems demonstrated the concept of mRNA-based therapeutics for expression of functional proteins, such as erythropoietin, factor IX and Cas9 [3] [4] [5] [6] [7] [8] [9] [10] . Lipid and lipid-like nanoparticles (LNPs and LLNs) are representative delivery systems for efficient delivery of RNAs [11] [12] [13] [14] [15] . Previously, we developed a series of lipid-like nanomaterials for mRNA delivery and improved their delivery efficiency by utilizing an orthogonal experimental design to fine-tune the molar ratio of formulation components [16] [17] [18] [19] . Among these nanomaterials, amino-ester nanomaterials allowed efficient delivery of Cas9 mRNA and gene editing in a mouse model [19] . Meanwhile, these amino-ester nanomaterials also exhibited tunable biodegradability since they were decorated with different ester groups. Because of these favorable properties, amino-ester nanomaterials merit further development for therapeutic and diagnostic applications.
Superparamagnetic iron oxide nanoparticles (SPIONs) are superparamagnetic contrast agents, which generate negative contrast enhancement in a T 2 -weighted image [20, 21] . SPIONs, with high transverse relaxivity (r 2 ), are compatible with live imaging in vivo [22] . After administration, SPIONs are capable of shortening the T 2 relaxation time of surrounding water protons and generate dark signals (negative contrast) [23] . Among the different types of magnetic resonance imaging (MRI) contrast agents, SPIONs are biocompatible and biodegradable [24] . However, SPIONs have limited cell membrane permeability [25] . To address this issue, lipid nanoparticles have been employed to enable the delivery of SPIONs into cells [26] [27] [28] . Based on previous findings, we hypothesized that amino-ester nanomaterials may be capable of simultaneous delivery of mRNA and SPIONs. Therefore, in this study, we investigated formulations using amino-ester nanomaterials to co-deliver mRNA and SPIONs. These nanoparticles possess dual functions that may potentially enable real-time and non-invasive visualization of diseased sites and the production of efficacious proteins for therapeutic applications in future.
Experimental

Materials
mRNAs encoding enhanced green fluorescent protein (eGFP) and firefly luciferase (FLuc) were purchased from TriLink Biotechnologies, Inc. (San Diego, CA, USA). 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 1,2-Dimyristoyl-sn-glycerol, methoxypolyethylene glycol (DMG-PEG 2000 ) was purchased from NOF America Corporation (White Plains, NY, USA). SPIONs were purchased from AC Diagnostic, Inc. (Fayetteville, AR, USA). Cholesterol (Chol) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Formulation of mRNA-SPION LLNs
MPA-Ab or TT3 (Fig. S1 in the Electronic Supplementary Material (ESM)) was formulated into nanoparticles with DOPE, Chol, DMG-PEG 2000 , SPIONs, and mRNA. Briefly, MPA-Ab or TT3 was mixed with DOPE, Chol, and DMG-PEG 2000 in ethanol at a previously identified optimal molar ratio of 20:30:40:0.75 [16] . mRNA and a various amount of SPIONs (0, 5, 10, or 20 μg) were mixed and further diluted in 10 mM citric acid buffer to prepare the aqueous phase. Subsequently, equal volumes of the ethanol and aqueous phases were mixed and then diluted with PBS (1:1, v/v) to prepare the desired nanomaterials.
mRNA-SPION LLN-mediated eGFP expression assay
The human hepatocellular carcinoma cell line Hep3B was purchased from American Type Culture Collection (Manassas, VA, USA) and was cultured in Eagle's Minimum Essential Medium supplemented with 10% fetal bovine serum. Cells were seeded in 6-well plates at a density of 2 × 10 5 cells/well. Twenty-four hours later, 15 μL of eGFP mRNA-SPION LLNs (150 ng mRNA equivalent) was added to the cells. After 24 h of treatment, the cells were trypsinized, washed, and collected. Green fluorescence intensity was quantified with a BD LSR II flow cytometer (San Jose, CA, USA). Nano Res. 2018, 11(10): 5596-5603
Orthogonal experimental design
The optimal formulation (molar ratio) for MPA-Ab LLNs was determined through an orthogonal experiment. Each formulation component (MPA-Ab, DOPE, Chol, DMG-PEG 2000 , and SPIONs) was assigned four levels, and a total of 16 combinations were evaluated. The optimal formulation molar ratio was identified using a data analysis method reported previously [16] .
Characterization of mRNA-SPION LLNs
Thirty microliters of mRNA-SPION LLNs was diluted in Milli-Q water. Then, the particle size and surface charge of mRNA-SPION LLNs were determined using a NanoZS Zetasizer (Malvern, Worcestershire, UK). Formulation MPA-Ab-8 was stored at 4 °C and its particle size was measured at day 1 and day 7 to test stability. Quant-iT™ RiboGreen RNA Assay Kit was used following the manufacturer's protocol to quantify the mRNA encapsulation efficiency.
Cryo-transmission electron microscopy (cryoTEM)
A small volume of MPA-Ab-8 LLNs (3 μL) was loaded onto a 400-mesh carbon-coated grid. The grid was immediately submerged into liquid ethane after extra liquid was blotted away. After a thin film of amorphous ice was formed, the grid was transferred to a Gatan 626 cryotransfer holder (Gatan, Pleasanton, CA, USA) while being kept at -196 °C in liquid nitrogen. The cryotransfer holder was subsequently loaded onto a Tecnai F20 S/TEM (Thermo-Fisher Scientific, Hillsboro, OR, USA) for image acquisition. Images were recorded at 200 kV with a nominal magnification of 80,000× under low-dose conditions.
Phantom MRI study
Standard SPION solutions were prepared by serial dilutions from a starting 
Cell-pellet MRI
MPA-Ab-8 LLNs and MPA-Ab-8 (without SPIONs) LLNs were formulated and dialyzed in PBS using 3.5 K MWCO Slide-A-Lyzer TM Dialysis Cassettes (Thermo Fisher Scientific, Waltham, MA, USA) one day before usage and were stored at 4 °C . Hep3B cells were cultured at 37 °C in a 5% carbon dioxide incubator to 90% confluency. Formulation MPA-Ab-8 was added to the cells at a final Fe 3 O 4 concentration of 0.003 or 0.015 mM. MPA-Ab-8 (without SPIONs) LLNs were used as a control. After 3 h of incubation, the cells were washed, trypsinized, centrifuged, and collected for MRI. T 2 -weighted images were acquired using a rapid acquisition with relaxation enhancement (RARE) protocol: TE = 12 ms, TR = 3,500 ms, rare factor = 8, NA = 1, FOV = 3 cm × 3 cm, matrix = 256 × 256, 1 mm slice thickness. T 2 mapping was performed following a multi-slice multi-echo protocol: TE = 9.8 ms, number of echoes = 36, TR = 4,000 ms, NA = 1, FOV = 3 cm × 3 cm, matrix = 256 × 256, 2 mm slice thickness.
Biodistribution study
All procedures used in animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) at The Ohio State University and were consistent with local, state, and federal regulations as applicable. FLuc mRNA-encapsulated MPA-Ab-8 LLNs were intravenously injected into an 8-week-old C57BL/6 mouse through the tail vein at an mRNA dose of 0.5 mg/kg. An untreated mouse served as a control. After 6 h of treatment, 150 μL of 30 mg·mL -1 D-luciferin was administered intraperitoneally. Eight minutes later, the mice were euthanized to collect heart, liver, spleen, lung, and kidneys. Bioluminescence radiance was quantified using an IVIS Lumina II imaging system (PerkinElmer, Inc., Waltham, MA, USA).
In-vivo MRI assay
An 8-week-old C57BL/6 mouse was anaesthetized, cannulated at the tail vein, and carefully transferred Nano Res. 2018, 11(10): 5596-5603 into the MRI scanner (BioSpec 94/30 Imaging System). T 2 -weighted images of spleen were acquired as no-treatment control. Formulation MPA-Ab-8 was then administered at a Fe 3 O 4 dose of 1.6 mg·kg -1 and T 2 -weighted images of spleen were captured immediately after administration. T 2 -weighted images were collected using the following parameters: RARE protocol, TE = 12.75 ms, TR = 3,723.8 ms, rare factor = 8, NA = 4, FOV = 2.8 cm × 2.8 cm, matrix = 286 × 286, 1 mm slice thickness, 30 slices. Agarose (1%) was used as a standard for signal intensity normalization.
Results and discussion
MPA-Ab (Fig. S1 in the ESM) is a representative example of biodegradable amino-ester LLNs that allows effective mRNA delivery according to our prior study [19] . In order to incorporate multiple functions in MPA-Ab LLNs, we encapsulated both SPIONs and mRNA. Formulation ratios are listed in Table S1 in the ESM. We evaluated these formulations in Hep3B cells and compared them with TT3 LLNs, a previously reported material (Fig. S1 in the ESM), as a positive control [16] . Through flow-cytometric analysis, we found that MPA-Ab LLNs displayed higher delivery efficiency of eGFP mRNA than TT3 LLNs with the same amount of SPIONs (0, 5, 10, or 20 μg) (Fig. 1) .
Moreover, the formulation MPA-Ab-S1 (addition of 5 μg SPIONs in the MPA-Ab LLNs) slightly improved mRNA delivery efficiency compared to MPA-Ab LLNs without SPIONs. In order to identify an optimal formulation of mRNA and SPION co-encapsulated MPA-Ab LLNs, we performed an orthogonal experiment. We assigned four levels to each formulation component (MPA-Ab, DOPE, Chol, DMG-PEG 2000 , and SPIONs) and then investigated their effects on mRNA delivery efficiency (Table S2 in the ESM). As shown in Fig. 2(a) , the eGFP mRNA delivery efficiency of MPA-Ab-8 LLNs was the highest among all the formulations, and it was approximately 2.5-fold higher than that of the original formulation MPA-Ab LLNs. Figures 2(b), 2(d) , and 2(e) show that formulation components MPA-Ab, Chol, and DMG-PEG 2000 reached their highest delivery efficiency at molar ratios of 25, 45, and 0.75, respectively. DOPE at a molar ratio of 60 reached the plateau (Fig. 2(c) ) and 5 μg of SPIONs was optimal for mRNA delivery (Fig. 2(f) ). Therefore, the optimal formulation identified based on the trend analysis had a molar ratio of MPA-Ab/DOPE/Chol/ PEG = 25/60/45/0.75 and an mRNA/SPIONs weight ratio of 1/2.5, that is the formulation MPA-Ab-8 in the orthogonal table. We also characterized the physicochemical properties of the formulations in the orthogonal table, including particle size, zeta potential, and mRNA encapsulation efficiency. The correlation of green fluorescence intensity with these three parameters was analyzed (Fig. S2 in the ESM) . The results showed that both particle size and zeta potential exhibited a significant positive correlation with green fluorescence intensity. No correlation was observed between green fluorescence intensity and mRNA encapsulation efficiency.
The features of SPIONs encapsulated in MPA-Ab-8 LLNs were studied. We first measured the size distribution of free SPIONs and MPA-Ab-8 LLNs, separately. Mean particle sizes were approximately 3 and 70 nm for free SPIONs and MPA-Ab-8 LLNs, respectively (Figs. 3(a) and 3(b) ). No typical size distribution pattern of SPIONs was detected for MPA-Ab-8 LLNs, suggesting that SPIONs were well encapsulated into the MPA-Ab-8 LLNs. In addition, MPA-Ab-8 LLNs were stable for at least one week when stored at 4 °C (Fig. 3(c) and Fig. S3 in the ESM). The particle size and morphology of MPA-Ab-8 LLNs was further determined by cryoTEM. As shown in Fig. 3(d) , the particles had a nearly spherical shape Nano Res. 2018, 11(10): 5596-5603 and their sizes were consistent with dynamic light scattering (DLS) measurement results.
We then studied the usability of MPA-Ab-8 LLNs for in-vitro MR imaging. First, we performed a phantom MRI assay to investigate the effects of LLNs on transverse relativity (r 2 ) of SPIONs [29] . Free SPIONs were used to prepare standards with five different Fe 3 O 4 concentrations. Formulation MPA-Ab-8 was diluted to the same Fe 3 O 4 concentrations as the standards. T 2 relaxation time for these samples was determined using a 9.4T MRI system. Transverse relativity was calculated using the following equation: T 2 -weighted images were acquired using the same system (Fig. 4(c) ). The PBS-treated group appeared bright on T 2 -weighted images, while increasing the amount of iron oxide was related to significant negative signal enhancement. Next, we performed T 2 mapping for quantification (Fig. 4(d) ). Cell pellets treated with 0.003 and 0.015 mM equivalent of iron oxide showed 90% and 44% relative T 2 relaxation time compared to control MPA-Ab-8 (without SPIONs)-treated cell pellets. Results from in-vitro studies demonstrated that MPA-Ab-8 LLNs are capable of simultaneously delivering both mRNA molecules and MRI contrast agent SPIONs.
Given the promising in-vitro results, we next investigated the potential of MPA-Ab-8 LLNs for in-vivo applications. To study the mRNA delivery efficiency of MPA-Ab-8 LLNs in vivo, FLuc mRNAencapsulated MPA-Ab-8 LLNs were administered to a mouse intravenously at an mRNA dose of 0.5 mg/kg. As shown in Fig. 5(a) , the MPA-Ab-8 FLuc LLNtreated mouse displayed strong luminescence signal at both the liver and the spleen, while no signal was detected in the non-treated control mouse. Next, we investigated whether the MPA-Ab-8 LLNs were able to induce a negative contrast enhancement in vivo. In this experiment, formulation MPA-Ab-8 was intravenously injected into a mouse via the tail vein at a Fe 3 O 4 dose of 1.6 mg/kg. Compared to the nontreated condition, there was a dramatic decrease in T 2 signal intensity at the spleen after administration (Fig. 5(b) ), which reduced the signal by 49% (Fig. S4 in the ESM). Based on the above results, formulation MPA-Ab-8 demonstrated its dual functions in vivo: delivering mRNA and achieving non-invasive MR imaging.
Conclusions
In summary, we optimized amino-ester lipid-based nanoparticles for simultaneous delivery of mRNA and SPIONs. MPA-Ab LLNs showed a significantly higher mRNA delivery efficiency in Hep3B cells than did TT3 LLNs. Using an orthogonal experiment, the optimal formulation MPA-Ab-8 was identified, with an approximately 2.5-fold increase in mRNA delivery efficiency in comparison to the original formulation. MPA-Ab-8 LLNs displayed great potential for delivering functional mRNA and producing MRI contrast signals in vivo. Overall, the dual-functional nanoparticles provide a useful tool for future theranostic applications. Nano Res. 2018, 11 (10) 
